# Cancer Immunology and Immunotherapy Program > **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $122,428 ## Abstract Cancer Immunology Program: Summary The mission of the Cancer Immunology (CI) Program is to understand the molecular basis and dynamic relationship between the immune system and cancer in order to translate this knowledge into novel and improved therapeutics. The CI Program has been restructured to focus on the pipeline from cancer immunology to immunotherapy, with research spanning from basic mechanistic studies in mouse models to investigating the response of the immune system in cancer patients receiving the latest immune-based therapeutics in the clinic. The CI Program has been strengthened by the establishment of the HDFCCC Cancer Immunotherapy Research Clinic in April 2016, allowing a more systematic evaluation of patients receiving immunotherapies as standard of care or as part of prospective clinical trials. In doing so, the goal is to enhance the efficacy of these approaches, but also to avoid the toxicities associated with the current generation of checkpoint blockade and CAR T cell-based therapies. CI Program members have made significant new scientific findings in the field of cancer immunology, particularly with respect to understanding the tumor microenvironment and basic mechanisms of interactions between immune cells and tumors. Program members have recently made many important contributions to the understanding of the interplay between the immune system and tumors, crossing each of the three themes. Theme 1: Identifying Immune System Mechanisms that Regulate Cancer Initiation and Progression Theme 2: Defining the Role of the Tumor Microenvironment in Cancer Immunity Theme 3: Developing Novel Approaches to Cancer Immunotherapy and Understanding Mechanisms Underlying their Efficacy and Toxicities CI Program: Key Metrics Membership (12 departments, 2 schools) 23 Full 17 Associate 6 Cancer-relevant Funding (direct costs as of $24,118,432 05/31/2017) NCI $4,117,666 17% Peer-reviewed $6,463,606 27% Non-peer-reviewed $13,537,159 56% Cancer-relevant Publications (1/2012-7/2017) 419 Inter-programmatic 96 23% Intra-Programmatic 38 9% High-Impact 177 42% Accruals to Clinical Trials (2016) 124 Therapeutic 124 30 Other Interventional 0 0 Non-interventional 0 0 In 2019-20, the HDFCCC developed a new strategic plan to guide decisions related to the research activities in the Center. The details of this strategic review process are discussed in the Leadership, Planning and Evaluation section of this report. Based on the research priorities identified in this plan, and with input from the EAB and the NCI, there have been changes to the structure of the CCSG-funded Research Programs to better support the evolving and innovative research of HDFCCC members. The new structure includes the merging of the previous Cancer Immunology Program and Hematopoietic Malignancies Program into a new Cancer Immunology and Immunotherapy Program, discussed here. The Cancer Immunology and Immunotherapy Program (CII) now has fo... ## Key facts - **NIH application ID:** 10169274 - **Project number:** 5P30CA082103-22 - **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - **Principal Investigator:** LEWIS Lee LANIER - **Activity code:** P30 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $122,428 - **Award type:** 5 - **Project period:** 1999-08-05 → 2023-05-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10169274 ## Citation > US National Institutes of Health, RePORTER application 10169274, Cancer Immunology and Immunotherapy Program (5P30CA082103-22). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10169274. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*